Cantor Fitzgerald analyst Charles Duncan maintains Vanda Pharma (NASDAQ:VNDA) with a Overweight and raises the price target from $11 to $13.
Cantor Fitzgerald Maintains Overweight on Vanda Pharma, Raises Price Target to $13
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.